Literature DB >> 2990634

IgM and IgG antibodies to human T cell lymphotropic retrovirus (HTLV-III) in lymphadenopathy syndrome and subjects at risk for AIDS in Italy.

F Aiuti, P Rossi, M C Sirianni, M Carbonari, M Popovic, M G Sarngadharan, L Contu, M Moroni, S Romagnani, R C Gallo.   

Abstract

A study was performed to assess the prevalence of specific antibodies to human T cell lymphotropic retrovirus (HTLV-III) in patients with lymphadenopathy syndrome, patients with the acquired immune deficiency syndrome (AIDS), and those at risk of AIDS. Serum samples were obtained from these groups and from healthy controls in selected cities in Italy, and antibodies to HTLV-III were measured by immunofluorescence assay and, in a few patients, by Western blotting. In addition, IgM antibody values were measured in 82 of those positive for HTLV-III. Altogether, 235 out of 320 patients with lymphadenopathy syndrome had antibodies to HTLV-III, the proportions being highest in haemophiliacs, homosexuals, and drug addicts from Rome; 11 out of 12 patients with AIDS had antibodies; 78 out of 439 subjects at risk for AIDS had antibodies; and six out of 30 patients with lymphadenopathy syndrome and positive for HTLV-III antibodies and nine of 52 patients at risk of AIDS had a detectable titre of IgM. HTLV-III is widespread in groups at risk of AIDS in Italy, and antibodies to HTLV-III are highly prevalent in patients with lymphadenopathy syndrome. A higher proportion of drug abusers were positive for antibodies than in previous studies. HTLV-III "infection" would appear to be spread mainly in compromised hosts, as none of the controls were positive for antibodies.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Antibodies; Biology; Developed Countries; Diseases; Drugs; Europe; Examinations And Diagnoses; Hematological Effects; Hiv Infections; Homosexuals; Immunity; Immunologic Factors; Italy; Laboratory Examinations And Diagnoses; Mediterranean Countries; Physiology; Population At Risk; Research Methodology; Research Report; Southern Europe; Viral Diseases

Mesh:

Substances:

Year:  1985        PMID: 2990634      PMCID: PMC1416387          DOI: 10.1136/bmj.291.6489.165

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  3 in total

1.  Prevalence of antibody to human T-lymphotropic virus type III in AIDS and AIDS-risk patients in Britain.

Authors:  R Cheingsong-Popov; R A Weiss; A Dalgleish; R S Tedder; D C Shanson; D J Jeffries; R B Ferns; E M Briggs; I V Weller; S Mitton
Journal:  Lancet       Date:  1984-09-01       Impact factor: 79.321

2.  Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion.

Authors:  D A Cooper; J Gold; P Maclean; B Donovan; R Finlayson; T G Barnes; H M Michelmore; P Brooke; R Penny
Journal:  Lancet       Date:  1985-03-09       Impact factor: 79.321

3.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

  3 in total
  9 in total

Review 1.  The natural history of human T lymphotropic virus-III infection: the cause of AIDS.

Authors:  M Melbye
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-04

2.  Abnormalities of in vitro immunoglobulin production in apparently healthy haemophiliacs: relationship with alterations of T cell subsets and with HTLV-III seropositivity.

Authors:  R Biagiotti; M G Giudizi; F Almerigogna; M Mazzetti; A Alessi; G F Del Prete; D Rafanelli; M Fiorilli; M Morfini; S Romagnani
Journal:  Clin Exp Immunol       Date:  1986-02       Impact factor: 4.330

3.  Genital secretory immune response to chronic simian immunodeficiency virus (SIV) infection: a comparison between intravenously and genitally inoculated rhesus macaques.

Authors:  C J Miller; D W Kang; M Marthas; Z Moldoveanu; H Kiyono; P Marx; J H Eldridge; J Mestecky; J R McGhee
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

4.  B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus.

Authors:  R D Schrier; J W Gnann; A J Langlois; K Shriver; J A Nelson; M B Oldstone
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

5.  Detection of anti-HIV-1 immunoglobulin M antibodies in patients with serologically proved HIV-1 infection.

Authors:  F Müller; K H Müller
Journal:  Infection       Date:  1988 Mar-Apr       Impact factor: 3.553

6.  Antibody response to human immunodeficiency virus in homosexual men. Relation of antibody specificity, titer, and isotype to clinical status, severity of immunodeficiency, and disease progression.

Authors:  J S McDougal; M S Kennedy; J K Nicholson; T J Spira; H W Jaffe; J E Kaplan; D B Fishbein; P O'Malley; C H Aloisio; C M Black
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

7.  HIV Apheresis Tags (HIVAT) Aided Elimination of Viremia.

Authors:  Marek Malecki; Bianka Saetre
Journal:  Mol Cell Ther       Date:  2018-06-21

Review 8.  Epidemic human immunodeficiency virus (HIV) infection among intravenous drug users (IVDU).

Authors:  R T D'Aquila; A B Williams
Journal:  Yale J Biol Med       Date:  1987 Nov-Dec

9.  Drug abuse and human immunodeficiency virus infection in Scotland.

Authors:  R P Brettle
Journal:  J R Soc Med       Date:  1987-05       Impact factor: 18.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.